Hepatitis C Virus

Studies from L.A. Sorbera et al have provided new data on hepatitis C virus

Published in Hepatitis Weekly, March 24th, 2008

"Interferon a. (IFN-alpha) was the standard treatment for chronic hepatitis C virus (HCV) for many years However, unmodified IFN-alpha has a short elimination half-life (t(1/2)) of about 2-3 h and requires frequent and prolonged injections. Researchers therefore initiated a search for modified IFNs with prolonged half-lives," investigators in Barcelona, Spain report.

"Pegylated IFN-alpha (PEG-IFN) emerged and comibination therapy including PEG-IFN and ribavirin has become the mainstay of treatment. However, the combination is associated with a high discontinuation rate, frequent dose modifications, low tolerability and a high nonresponder rate. In the continued search...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2008-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry